Immunotherapy for hepatocellular carcinoma: Current status and future perspectives

Table 1 Immunotherapy with immune checkpoint inhibitor in hepatocellular carcinoma (clinical trial with reported results)

Treatment	Patients, n	ORR%	OS in mo	Ref.
Atezolizumab	59	17 (5)	NA	[44]
Nivolumab	371	15(4)	16.4	[21]
Camrelizumab	217	15 (0)	13.8	[165]
Pembrolizumab	278	18 (2)	13.9	[36]
Durvalumab	104	11 (0)	13.6	[46]
Tremelimumab	69	7 (0)	15.1	[46]
Durvalumab and tremelimumab	159	9.5-24.0 (1-2)	11.3-18.7	[46]
Pembrolizumab and levantinib	100	36 (1)	22	[20]
Nivolumab and ipilimumab	148	31-32 (0-8)	12.5-22.8	[42]
Atezolizumab and bevacizumab	336	27 (6)	NE	[20]
Nivolumab and cabozantinib	36	14 (3)	21.5	[42]
Nivolumab, ipilimumab and cabozantinib	35	31 (6)	NE	[42]

NA: Not available; NE: Not evaluable; ORR: Overall response rate; OS: Overall survival.